10 new technologies tackling urgent challenges from autoimmune disease to cancer win funding from Blavatnik Biomedical Accelerator.

A team of Harvard and Sloan Kettering scientists has developed compounds that can target and degrade proteins associated with acute myeloid leukemia (AML) and nearly doubled the life expectancy of mice with cancer in laboratory tests.

Harvard, Merck to collaborate on research led by Harvard immunologist Arlene Sharpe, seeking to identify new pathways for the treatment of cancer

Licensing and collaboration agreement aims to bring biomaterial-based cancer immunotherapies into clinical development